Adverse Reaction to Drug Completed Phase 2 Trials for Tegafur-uracil (DB09327)

IndicationStatusPhase
DBCOND0042486 (Adverse Reaction to Drug)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02447679Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma RecurrencePrevention